Body Composition

Survodutide

Survodutide (Glucagon/GLP-1 Receptor Agonist)

Dual glucagon/GLP-1 agonist studied for weight and liver outcomes

Research Status: Investigational; Phase II/III trials ongoing BI 456906
Mechanism of Action

How it works

Survodutide activates both the glucagon and GLP-1 receptors. The glucagon-receptor component is investigated for increased energy expenditure and hepatic effects, while GLP-1 activity supports appetite and glucose regulation.

Areas of Research

What the research explores

In published research, Survodutide has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Dual mechanism studied for body weight reduction
  • Investigated specifically for liver (MASH) outcomes
  • Researched for energy expenditure via glucagon receptor
  • Active Phase II/III clinical program
Research Highlight

A Phase II trial reported meaningful improvement in liver fibrosis/steatohepatitis markers (MASH) alongside weight reduction.

Safety Profile

Adverse events & gaps

Investigational. Gastrointestinal effects most commonly reported; full profile under study.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.